Tim Smith

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

In this interview, Neal Bhatia, MD, reacts to the FDA’s approval of roflumilast foam as well as the approval’s background and implications for patients with the inflammatory skin condition.

The approval of the once-daily, steroid free foam marks the first approval of a drug by the FDA for the skin condition with a new mechanism of action in around 2 decades.

This announcement may be considered further progress in the implementation of the FDA Overdose Prevention Framework designed to prevent overdoses and reduce mortality.

These data indicate that the early detection of vitiligo may be improved through an assessment of transplant recipients and using a multidisciplinary approach.

These results highlight the potential of preventing increasing CKD burden and of preventing subsequent cardiovascular conditions, especially given current rates of obesity among adolescents.

These data helped to verify the MDRD-4 and CKD-EPI equations’ accuracy in the estimation of GFR among the Brazilian population.

This review of telehealth use among adolescents with allergic conditions synthesized evidence on patients’ transition to self-management of their conditions.

This web-based research is the first conducted to assess the burden of disease and treatment satisfaction among those in Japan with PN.

The submissions to both agencies were based upon positive results from the BASIS trial that had been presented at the American Society of Hematology Annual Meeting.

Given the lack of widespread awareness of the magnitude and prevalence of the public’s stigma toward people with acne, this research sought to expand upon this body of research.

2023 was a year of both advancements and setbacks for various treatments, and this discussion covers the most significant moves by the FDA this year.

These findings presented at ASH show promise for future studies on GBT02601 as a potential alternative to voxelotor for sickle cell disease.

This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.

These findings suggest the need for additional clinical evaluations in trials on a larger scale to allow for confirmation of the efficacy and safety of the treatment.

This new data may help to indicate a potential common immunological mechanism, allowing for greater assessment of the effects of therapeutic agents and treatment combinations.

These new findings represent the only PTC case to look at such a unique number of concurrent comorbidities in current medical literature.

These phase 2 data indicate that the implant may be a helpful addition to clinicians’ interventional glaucoma armamentarium for patients.

During this interview, Perkins described a recent landmark study which yielded some unique findings regarding pathogen-detection.

These results in the subgroup analysis, seen among individuals who were both identified as Asian and non-Asian, align with data published previously in the overall population.

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

This new data align with the acknowledged necessity for a disruption of the itch–scratch cycle in moderate-to-severe AD treatment among patients.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

The Dermatology Month in Review for dermatology features 2 interviews, findings from recent long-term data, and a discussion of the FDA’s approval of secukinumab for HS.

In this retrospective review of medical charts, trends in systemic treatment use among psoriasis patients in Japan pointed to several notable findings.

This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.